Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing...
Gespeichert in:
| Veröffentlicht in: | Journal of hematology and oncology 2013-09, Vol.6 (1), p.67-67, Article 67 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Journal of hematology and oncology |
| container_volume | 6 |
| creator | Capello, Michela Cappello, Paola Linty, Federica Caterina Chiarle, Roberto Sperduti, Isabella Novarino, Anna Salacone, Paola Mandili, Giorgia Naccarati, Alessio Sacerdote, Carlotta Beghelli, Stefania Bersani, Samantha Barbi, Stefano Bassi, Claudio Scarpa, Aldo Nisticò, Paola Giovarelli, Mirella Vineis, Paolo Milella, Michele Novelli, Francesco |
| description | Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.
The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC analyses (P |
| doi_str_mv | 10.1186/1756-8722-6-67 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3844582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534769201</galeid><sourcerecordid>A534769201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-d1a048dbe337da4bea477f5df460ac324c071154cedfd71297e15c96b81a0f0d3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqVw5YgsISEuKbbj2MkFaVWVglSJC5ytiT3JuvLai51UKr8eRy3bLScu_ppnXs2M36p6y-g5Y538xFQr605xXstaqmfV6eHh-dH5pHqV8w2lkvWcvqxOuKCM9h07rfJmmSOE2Q3ROsxkjuTyd3KBQEICgSAkf0eymwKJI9lDMAlhdoaYcsRECrlddhByge16mzBgiYMvaRgmFxATWrKLS8ayWvT5dfViBJ_xzcN-Vv38cvnj4mt9_f3q28XmujatknNtGVDR2QGbRlkQA4JQamztKCQF03BhqGKsFQbtaBXjvULWml4OXUkcqW3Oqs_3uvtl2KE1GOYEXu-T20G60xGcfhoJbquneKubToi240Xg44NAir8WzLPeuWzQewhY-tFM9LLrOf8vtO1LrVz2BX3_D3oTlxTKJArVsNI75d0jNYFH7cIYS4lmFdWbthFKlp9khfpwRG0R_LzN0S-ziyE_Bc_vQZNizgnHwxgY1auT9GoWvZpFSy1VSXh3PLwD_tc6zR93yMMJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1431576028</pqid></control><display><type>article</type><title>Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>PubMed Central Open Access</source><creator>Capello, Michela ; Cappello, Paola ; Linty, Federica Caterina ; Chiarle, Roberto ; Sperduti, Isabella ; Novarino, Anna ; Salacone, Paola ; Mandili, Giorgia ; Naccarati, Alessio ; Sacerdote, Carlotta ; Beghelli, Stefania ; Bersani, Samantha ; Barbi, Stefano ; Bassi, Claudio ; Scarpa, Aldo ; Nisticò, Paola ; Giovarelli, Mirella ; Vineis, Paolo ; Milella, Michele ; Novelli, Francesco</creator><creatorcontrib>Capello, Michela ; Cappello, Paola ; Linty, Federica Caterina ; Chiarle, Roberto ; Sperduti, Isabella ; Novarino, Anna ; Salacone, Paola ; Mandili, Giorgia ; Naccarati, Alessio ; Sacerdote, Carlotta ; Beghelli, Stefania ; Bersani, Samantha ; Barbi, Stefano ; Bassi, Claudio ; Scarpa, Aldo ; Nisticò, Paola ; Giovarelli, Mirella ; Vineis, Paolo ; Milella, Michele ; Novelli, Francesco</creatorcontrib><description>Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.
The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC analyses (P < 0.0001). This observation was confirmed in prediagnostic sera from the EPIC prospective study in patients who eventually developed PDAC (with a mean time lag of 61.2 months between blood drawing and PDAC diagnosis). A combination of Ezrin-autoantibodies with CA19.9 serum levels and phosphorylated α-Enolase autoantibodies showed an overall diagnostic accuracy of 0.96 ± 0.02.
Autoantibodies against Ezrin are induced early in PDAC and their combination with other serological markers may provide a predictive and diagnostic signature.</description><identifier>ISSN: 1756-8722</identifier><identifier>EISSN: 1756-8722</identifier><identifier>DOI: 10.1186/1756-8722-6-67</identifier><identifier>PMID: 24010981</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adenocarcinoma ; Adult ; Age ; Aged ; Aged, 80 and over ; Analysis ; Animals ; Antigens ; Autoantibodies - blood ; Autoantibodies - immunology ; Autoimmune diseases ; Cancer therapies ; Carcinoma, Pancreatic Ductal - blood ; Carcinoma, Pancreatic Ductal - diagnosis ; Carcinoma, Pancreatic Ductal - immunology ; Cross-Sectional Studies ; Cytoskeletal Proteins - blood ; Cytoskeletal Proteins - immunology ; Disease ; Disease Models, Animal ; Enzyme-linked immunosorbent assay ; Epidemiology ; Female ; Genetic Engineering ; Hematology ; Hospitals ; Humans ; Immune response ; Male ; Mass spectrometry ; Medical research ; Medicine, Experimental ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Middle Aged ; Nutrition research ; Oncology ; Pancreas ; Pancreatic cancer ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - immunology ; Physiological aspects ; Physiological research ; Prospective Studies ; Proteins ; Tumors</subject><ispartof>Journal of hematology and oncology, 2013-09, Vol.6 (1), p.67-67, Article 67</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Capello et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Capello et al.; licensee BioMed Central Ltd. 2013 Capello et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-d1a048dbe337da4bea477f5df460ac324c071154cedfd71297e15c96b81a0f0d3</citedby><cites>FETCH-LOGICAL-c576t-d1a048dbe337da4bea477f5df460ac324c071154cedfd71297e15c96b81a0f0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844582/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844582/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24010981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capello, Michela</creatorcontrib><creatorcontrib>Cappello, Paola</creatorcontrib><creatorcontrib>Linty, Federica Caterina</creatorcontrib><creatorcontrib>Chiarle, Roberto</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Novarino, Anna</creatorcontrib><creatorcontrib>Salacone, Paola</creatorcontrib><creatorcontrib>Mandili, Giorgia</creatorcontrib><creatorcontrib>Naccarati, Alessio</creatorcontrib><creatorcontrib>Sacerdote, Carlotta</creatorcontrib><creatorcontrib>Beghelli, Stefania</creatorcontrib><creatorcontrib>Bersani, Samantha</creatorcontrib><creatorcontrib>Barbi, Stefano</creatorcontrib><creatorcontrib>Bassi, Claudio</creatorcontrib><creatorcontrib>Scarpa, Aldo</creatorcontrib><creatorcontrib>Nisticò, Paola</creatorcontrib><creatorcontrib>Giovarelli, Mirella</creatorcontrib><creatorcontrib>Vineis, Paolo</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Novelli, Francesco</creatorcontrib><title>Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models</title><title>Journal of hematology and oncology</title><addtitle>J Hematol Oncol</addtitle><description>Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.
The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC analyses (P < 0.0001). This observation was confirmed in prediagnostic sera from the EPIC prospective study in patients who eventually developed PDAC (with a mean time lag of 61.2 months between blood drawing and PDAC diagnosis). A combination of Ezrin-autoantibodies with CA19.9 serum levels and phosphorylated α-Enolase autoantibodies showed an overall diagnostic accuracy of 0.96 ± 0.02.
Autoantibodies against Ezrin are induced early in PDAC and their combination with other serological markers may provide a predictive and diagnostic signature.</description><subject>Adenocarcinoma</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Animals</subject><subject>Antigens</subject><subject>Autoantibodies - blood</subject><subject>Autoantibodies - immunology</subject><subject>Autoimmune diseases</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - blood</subject><subject>Carcinoma, Pancreatic Ductal - diagnosis</subject><subject>Carcinoma, Pancreatic Ductal - immunology</subject><subject>Cross-Sectional Studies</subject><subject>Cytoskeletal Proteins - blood</subject><subject>Cytoskeletal Proteins - immunology</subject><subject>Disease</subject><subject>Disease Models, Animal</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Genetic Engineering</subject><subject>Hematology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immune response</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Middle Aged</subject><subject>Nutrition research</subject><subject>Oncology</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - immunology</subject><subject>Physiological aspects</subject><subject>Physiological research</subject><subject>Prospective Studies</subject><subject>Proteins</subject><subject>Tumors</subject><issn>1756-8722</issn><issn>1756-8722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkk1v1DAQhiMEoqVw5YgsISEuKbbj2MkFaVWVglSJC5ytiT3JuvLai51UKr8eRy3bLScu_ppnXs2M36p6y-g5Y538xFQr605xXstaqmfV6eHh-dH5pHqV8w2lkvWcvqxOuKCM9h07rfJmmSOE2Q3ROsxkjuTyd3KBQEICgSAkf0eymwKJI9lDMAlhdoaYcsRECrlddhByge16mzBgiYMvaRgmFxATWrKLS8ayWvT5dfViBJ_xzcN-Vv38cvnj4mt9_f3q28XmujatknNtGVDR2QGbRlkQA4JQamztKCQF03BhqGKsFQbtaBXjvULWml4OXUkcqW3Oqs_3uvtl2KE1GOYEXu-T20G60xGcfhoJbquneKubToi240Xg44NAir8WzLPeuWzQewhY-tFM9LLrOf8vtO1LrVz2BX3_D3oTlxTKJArVsNI75d0jNYFH7cIYS4lmFdWbthFKlp9khfpwRG0R_LzN0S-ziyE_Bc_vQZNizgnHwxgY1auT9GoWvZpFSy1VSXh3PLwD_tc6zR93yMMJ</recordid><startdate>20130906</startdate><enddate>20130906</enddate><creator>Capello, Michela</creator><creator>Cappello, Paola</creator><creator>Linty, Federica Caterina</creator><creator>Chiarle, Roberto</creator><creator>Sperduti, Isabella</creator><creator>Novarino, Anna</creator><creator>Salacone, Paola</creator><creator>Mandili, Giorgia</creator><creator>Naccarati, Alessio</creator><creator>Sacerdote, Carlotta</creator><creator>Beghelli, Stefania</creator><creator>Bersani, Samantha</creator><creator>Barbi, Stefano</creator><creator>Bassi, Claudio</creator><creator>Scarpa, Aldo</creator><creator>Nisticò, Paola</creator><creator>Giovarelli, Mirella</creator><creator>Vineis, Paolo</creator><creator>Milella, Michele</creator><creator>Novelli, Francesco</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20130906</creationdate><title>Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models</title><author>Capello, Michela ; Cappello, Paola ; Linty, Federica Caterina ; Chiarle, Roberto ; Sperduti, Isabella ; Novarino, Anna ; Salacone, Paola ; Mandili, Giorgia ; Naccarati, Alessio ; Sacerdote, Carlotta ; Beghelli, Stefania ; Bersani, Samantha ; Barbi, Stefano ; Bassi, Claudio ; Scarpa, Aldo ; Nisticò, Paola ; Giovarelli, Mirella ; Vineis, Paolo ; Milella, Michele ; Novelli, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-d1a048dbe337da4bea477f5df460ac324c071154cedfd71297e15c96b81a0f0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Animals</topic><topic>Antigens</topic><topic>Autoantibodies - blood</topic><topic>Autoantibodies - immunology</topic><topic>Autoimmune diseases</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - blood</topic><topic>Carcinoma, Pancreatic Ductal - diagnosis</topic><topic>Carcinoma, Pancreatic Ductal - immunology</topic><topic>Cross-Sectional Studies</topic><topic>Cytoskeletal Proteins - blood</topic><topic>Cytoskeletal Proteins - immunology</topic><topic>Disease</topic><topic>Disease Models, Animal</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Genetic Engineering</topic><topic>Hematology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immune response</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Middle Aged</topic><topic>Nutrition research</topic><topic>Oncology</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - immunology</topic><topic>Physiological aspects</topic><topic>Physiological research</topic><topic>Prospective Studies</topic><topic>Proteins</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capello, Michela</creatorcontrib><creatorcontrib>Cappello, Paola</creatorcontrib><creatorcontrib>Linty, Federica Caterina</creatorcontrib><creatorcontrib>Chiarle, Roberto</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Novarino, Anna</creatorcontrib><creatorcontrib>Salacone, Paola</creatorcontrib><creatorcontrib>Mandili, Giorgia</creatorcontrib><creatorcontrib>Naccarati, Alessio</creatorcontrib><creatorcontrib>Sacerdote, Carlotta</creatorcontrib><creatorcontrib>Beghelli, Stefania</creatorcontrib><creatorcontrib>Bersani, Samantha</creatorcontrib><creatorcontrib>Barbi, Stefano</creatorcontrib><creatorcontrib>Bassi, Claudio</creatorcontrib><creatorcontrib>Scarpa, Aldo</creatorcontrib><creatorcontrib>Nisticò, Paola</creatorcontrib><creatorcontrib>Giovarelli, Mirella</creatorcontrib><creatorcontrib>Vineis, Paolo</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Novelli, Francesco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capello, Michela</au><au>Cappello, Paola</au><au>Linty, Federica Caterina</au><au>Chiarle, Roberto</au><au>Sperduti, Isabella</au><au>Novarino, Anna</au><au>Salacone, Paola</au><au>Mandili, Giorgia</au><au>Naccarati, Alessio</au><au>Sacerdote, Carlotta</au><au>Beghelli, Stefania</au><au>Bersani, Samantha</au><au>Barbi, Stefano</au><au>Bassi, Claudio</au><au>Scarpa, Aldo</au><au>Nisticò, Paola</au><au>Giovarelli, Mirella</au><au>Vineis, Paolo</au><au>Milella, Michele</au><au>Novelli, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models</atitle><jtitle>Journal of hematology and oncology</jtitle><addtitle>J Hematol Oncol</addtitle><date>2013-09-06</date><risdate>2013</risdate><volume>6</volume><issue>1</issue><spage>67</spage><epage>67</epage><pages>67-67</pages><artnum>67</artnum><issn>1756-8722</issn><eissn>1756-8722</eissn><abstract>Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneously developing PDAC; and (b) to test their diagnostic/predictive value in newly diagnosed PDAC patients and in prediagnostic sera.
The serum reactivity of GEM from inception to invasive cancer, and in resectable or advanced human PDAC was tested by two-dimensional electrophoresis Western blot against proteins from murine and human PDAC cell lines, respectively. A common mouse-to-human autoantibody signature, directed against six antigens identified by MALDI-TOF mass spectrometry, was determined. Of the six antigens, Ezrin displayed the highest frequency of autoantibodies in GEM with early disease and in PDAC patients with resectable disease. The diagnostic value of Ezrin-autoantibodies to discriminate PDAC from controls was further shown by ELISA and ROC analyses (P < 0.0001). This observation was confirmed in prediagnostic sera from the EPIC prospective study in patients who eventually developed PDAC (with a mean time lag of 61.2 months between blood drawing and PDAC diagnosis). A combination of Ezrin-autoantibodies with CA19.9 serum levels and phosphorylated α-Enolase autoantibodies showed an overall diagnostic accuracy of 0.96 ± 0.02.
Autoantibodies against Ezrin are induced early in PDAC and their combination with other serological markers may provide a predictive and diagnostic signature.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>24010981</pmid><doi>10.1186/1756-8722-6-67</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8722 |
| ispartof | Journal of hematology and oncology, 2013-09, Vol.6 (1), p.67-67, Article 67 |
| issn | 1756-8722 1756-8722 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3844582 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals; PubMed Central Open Access |
| subjects | Adenocarcinoma Adult Age Aged Aged, 80 and over Analysis Animals Antigens Autoantibodies - blood Autoantibodies - immunology Autoimmune diseases Cancer therapies Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - diagnosis Carcinoma, Pancreatic Ductal - immunology Cross-Sectional Studies Cytoskeletal Proteins - blood Cytoskeletal Proteins - immunology Disease Disease Models, Animal Enzyme-linked immunosorbent assay Epidemiology Female Genetic Engineering Hematology Hospitals Humans Immune response Male Mass spectrometry Medical research Medicine, Experimental Mice Mice, Inbred C57BL Mice, Transgenic Middle Aged Nutrition research Oncology Pancreas Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - immunology Physiological aspects Physiological research Prospective Studies Proteins Tumors |
| title | Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T03%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoantibodies%20to%20Ezrin%20are%20an%20early%20sign%20of%20pancreatic%20cancer%20in%20humans%20and%20in%20genetically%20engineered%20mouse%20models&rft.jtitle=Journal%20of%20hematology%20and%20oncology&rft.au=Capello,%20Michela&rft.date=2013-09-06&rft.volume=6&rft.issue=1&rft.spage=67&rft.epage=67&rft.pages=67-67&rft.artnum=67&rft.issn=1756-8722&rft.eissn=1756-8722&rft_id=info:doi/10.1186/1756-8722-6-67&rft_dat=%3Cgale_pubme%3EA534769201%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1431576028&rft_id=info:pmid/24010981&rft_galeid=A534769201&rfr_iscdi=true |